Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ALRN

ALRN - Aileron Therapeutics Inc Stock Price, Fair Value and News

4.80USD+0.14 (+3.00%)Market Closed
Watchlist

Market Summary

USD4.80+0.14
Market Closed
3.00%

ALRN Stock Price

View Fullscreen

ALRN RSI Chart

ALRN Valuation

Market Cap

21.1M

Price/Earnings (Trailing)

-1.63

Price/Free Cashflow

-1.53

ALRN Price/Sales (Trailing)

ALRN Profitability

Return on Equity

-115.56%

Return on Assets

-100.92%

Free Cashflow Yield

-65.48%

ALRN Fundamentals

ALRN Revenue

ALRN Earnings

Earnings (TTM)

-12.9M

Earnings Growth (Yr)

71.31%

Earnings Growth (Qtr)

-2.24%

Breaking Down ALRN Revenue

Last 7 days

-2.3%

Last 30 days

19.3%

Last 90 days

144.3%

Trailing 12 Months

81.8%

How does ALRN drawdown profile look like?

ALRN Financial Health

Current Ratio

7.88

ALRN Investor Care

Buy Backs (1Y)

0.00%

Diluted EPS (TTM)

-2.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20170000
20160000

Tracking the Latest Insider Buys and Sells of Aileron Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 15, 2023
windsor james brian
bought
758
3.37
225
president and coo
Nov 20, 2023
windsor james brian
bought
9,987
1.9675
5,076
president and coo
Jan 08, 2021
satter muneer a
bought
9,900,000
1.1
9,000,000
see remarks
Jun 15, 2020
ambros reinhard j.
bought
7,076
1.22
5,800
-
Jun 08, 2020
von rickenbach josef h
bought
249,999
1.1
227,272
-
Jun 08, 2020
satter muneer a
bought
4,070,000
1.1
3,700,000
-
Nov 15, 2019
bailey jeffrey allen
bought
19,962
0.51
39,142
-
Nov 14, 2019
bailey jeffrey allen
bought
8,087
0.51
15,858
-
Nov 12, 2019
bailey jeffrey allen
bought
10,543
0.53
19,894
-
Sep 13, 2019
von rickenbach josef h
bought
24,255
0.9702
25,000
-

1–10 of 22

Which funds bought or sold ALRN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
BANK OF AMERICA CORP /DE/
unchanged
-
191
381
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
sold off
-100
-30,434
-
-%
Feb 14, 2024
GAGNON SECURITIES LLC
new
-
115,685
115,685
0.03%
Feb 14, 2024
VANGUARD GROUP INC
added
0.95
62,201
122,901
-%
Feb 13, 2024
ACADIAN ASSET MANAGEMENT LLC
unchanged
-
-
-
-%
Feb 13, 2024
MORGAN STANLEY
unchanged
-
1,911
3,811
-%
Feb 13, 2024
FMR LLC
new
-
152
152
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
reduced
-50.63
-67.00
6,787
-%
Feb 13, 2024
BlackRock Inc.
unchanged
-
289
576
-%

1–10 of 27

Are Funds Buying or Selling ALRN?

Are funds buying ALRN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ALRN
No. of Funds

Unveiling Aileron Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
biotechnology value fund l p
-
0
SC 13G/A
Feb 05, 2024
kapnick scott
0%
0
SC 13G/A
Nov 13, 2023
bios fund i, lp
9.99%
539,293
SC 13G
Nov 03, 2023
satter muneer a
19.9%
1,007,488
SC 13D/A
Feb 14, 2023
biotechnology value fund l p
2.8%
125,755
SC 13G/A
Feb 14, 2023
kapnick scott
8.4%
379,608
SC 13G/A
Feb 14, 2022
kapnick scott
8.4%
7,592,222
SC 13G/A
Feb 10, 2021
jennison associates llc
3.7%
1,542,288
SC 13G/A
Feb 09, 2021
prudential financial inc
3.65%
0
SC 13G/A
Jan 19, 2021
biotechnology value fund l p
3.3%
2,779,536
SC 13G

Recent SEC filings of Aileron Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
8-K
Current Report
Feb 05, 2024
EFFECT
EFFECT
Feb 05, 2024
SC 13G/A
Major Ownership Report
Jan 31, 2024
DEFA14A
DEFA14A
Jan 29, 2024
S-3
S-3
Jan 29, 2024
8-K
Current Report
Jan 29, 2024
ARS
ARS
Jan 29, 2024
DEF 14A
DEF 14A
Jan 29, 2024
S-8
Employee Benefits Plan

Peers (Alternatives to Aileron Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aileron Therapeutics Inc News

Latest updates
InvestorsObserver24 Jan 202408:00 am

Aileron Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-8.4%12,82213,99117,15722,00727,23233,77040,25548,48154,76860,53164,67116,34122,23926,12520,37326,47333,95240,19322,39930,31238,133
  Current Assets-8.3%12,79313,95217,10521,87327,05433,55039,99348,17754,42360,15264,32416,32615,97419,67013,68719,55026,49732,55914,38921,77530,053
    Cash Equivalents-8.3%12,06913,1677,7835,1944,8397,6287,4493,6007,60310,74819,2837,0467,85017,12410,6975,3116,86710,15711,27210,6357,716
  Net PPE-25.6%29.0039.0052.0070.0084.0098.0011312814415398.0015.001471642252953613793987,2906,832
Liabilities35.7%1,6241,1972,8843,3844,5365,1514,1464,5774,6594,4013,2524,1799,7819,47110,60410,42511,13610,2099,55210,71212,102
  Current Liabilities35.7%1,6241,1972,8843,3844,5365,1514,1464,5084,5604,2733,0733,9605,2494,9266,1435,8396,4285,3874,6235,3707,105
Shareholder's Equity-12.5%11,19812,79414,27318,62322,69628,61936,10943,90450,10956,13061,41912,16212,45816,6549,76916,04822,81629,98412,84719,60026,031
  Retained Earnings-0.7%-281,178-279,351-277,564-272,785-268,238-261,870-253,878-245,456-238,657-231,953-226,267-219,292-214,296-209,273-204,883-198,135-190,900-183,151-175,979-168,493-161,459
  Additional Paid-In Capital0.1%292,285292,056291,756291,365290,941290,499289,971289,282288,674287,987287,603231,412226,715225,890214,625214,148213,671213,083188,811188,083187,478
Shares Outstanding0%4,5414,5414,5414,5414,5414,5374,5344,5294,5274,3474,1692,1901,6401,476-------
Float------19,137,097---91,635,955---36,630---20,008---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations47.4%-1,640-3,116-4,661-4,409-6,971-5,685-7,800-6,255-7,260-3,763-6,476-4,689-5,043-5,072-5,672-6,305-6,976-5,692-7,501-6,663-6,878
  Share Based Compensation-23.7%229300391424442528689607660362631363465560505479614460563591588
Cashflow From Investing-93.6%5428,5007,2504,7644,1825,86411,6492,2514,089-4,798-37,459-357-4,52923911,0584,7643,737-19,2887,9738,3051,404
Cashflow From Financing--------1.0026.0026.0055,6044,24229811,260--15.00-51.0023,8651651,2771,210

ALRN Income Statement

2023-09-30
Condensed Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenue$ 0$ 0$ 0$ 0
Operating expenses:    
Research and development224,2392,01915,565
General and administrative1,9552,2436,0277,379
Restructuring and Other6 940 
Total operating expenses1,9836,4828,98622,944
Loss from operations(1,983)(6,482)(8,986)(22,944)
Interest income155110322180
Other income (expense), net14271(18)
Net loss$ (1,827)$ (6,368)$ (8,393)$ (22,782)
Net loss per share - basic$ (0.4)$ (1.4)$ (1.85)$ (5.02)
Net loss per share - diluted$ (0.4)$ (1.4)$ (1.85)$ (5.02)
Weighted average common shares outstanding - basic4,541,1674,541,1794,541,1674,538,707
Weighted average common shares outstanding - diluted4,541,1674,541,1794,541,1674,538,707
Comprehensive loss:    
Net loss$ (1,827)$ (6,368)$ (8,393)$ (22,782)
Other comprehensive loss:    
Unrealized gain (loss) on investments, net of tax of $02348(85)
Total other comprehensive gain (loss)2348(85)
Total comprehensive loss$ (1,825)$ (6,365)$ (8,345)$ (22,867)

ALRN Balance Sheet

2023-09-30
Condensed Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 12,069$ 5,194
Investments 16,048
Prepaid expenses and other current assets699606
Restricted cash2525
Total current assets12,79321,873
Operating lease, right-of-use asset 40
Other non-current assets 24
Property and equipment, net2970
Total assets12,82222,007
Current liabilities:  
Accounts payable4841,720
Accrued expenses and other current liabilities1,1401,631
Operating lease liability, current portion 33
Total current liabilities1,6243,384
Total liabilities1,6243,384
Commitments and contingencies (Note 12)
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively
Common stock, $0.001 par value; 45,000,000 shares authorized at September 30, 2023 and December 31, 2022, respectively; 4,541,167 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively9191
Additional paid-in capital292,285291,365
Accumulated other comprehensive loss (48)
Accumulated deficit(281,178)(272,785)
Total stockholders’ equity11,19818,623
Total liabilities and stockholders’ equity$ 12,822$ 22,007
ALRN
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
 CEO
 WEBSITEwww.aileronrx.com
 EMPLOYEES6

Aileron Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Aileron Therapeutics Inc? What does ALRN stand for in stocks?

ALRN is the stock ticker symbol of Aileron Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aileron Therapeutics Inc (ALRN)?

As of Thu Feb 22 2024, market cap of Aileron Therapeutics Inc is 21.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALRN stock?

You can check ALRN's fair value in chart for subscribers.

What is the fair value of ALRN stock?

You can check ALRN's fair value in chart for subscribers. The fair value of Aileron Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aileron Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALRN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aileron Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALRN is over valued or under valued. Whether Aileron Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aileron Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALRN.